Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2004

01-07-2004 | Original Research Article

Insulin Disposition in the Lung Following Oral Inhalation in Humans

A Meta-Analysis of its Pharmacokinetics

Author: Dr Masahiro Sakagami

Published in: Clinical Pharmacokinetics | Issue 8/2004

Login to get access

Abstract

Background

Oral inhalation of insulin potentially offers non-invasive treatment and better glycaemic control in diabetes by virtue of its apparently faster absorption into the systemic circulation compared with subcutaneous injection. Nevertheless, the lung kinetics of inhaled insulin in humans have yet to be fully clarified because of the complexity of insulin-glucose (patho)physiology and the difficulty in approximating the inhaled dose. As a result, there remains considerable debate on the mechanisms of absorption and metabolism of insulin in the lung. Objectives: To develop and apply a physiologically realistic insulin-glucose kinetic model to a meta-analysis of insulin-glucose profiles from well-controlled clinical studies of inhaled insulin published in the literature, and thereby, to derive the kinetic descriptors of insulin in the lung following inhalation through curve fitting.

Model development

The model assumed first-order absorption (ka,L) and parallel non-absorptive loss (kmm,L), the latter primarily occurring via metabolism and mucociliary clearance in the lung, alongside two systemic compartments. Where necessary, glucose-dependent endogenous pancreatic insulin secretion was also taken into account by using blood glucose data as the second independent variable.

Results

Despite the model’s simplicity and the use of mean data, 16 insulin-glucose profiles from ten clinical studies were successfully fitted to the model, yielding values for the rate constants ka,L and kmm,L. Whole serum insulin profiles were rate-determined by ka,L and kmm,L combined, representing ‘flip-flop’ pharmacokinetics. The best estimate for ka,L was found to be 0.020-0.032 h-1, effectively unchanged across doses (0.3–1.8 IU/kg), formulations (powder vs liquid) and subjects (healthy vs diabetic), suggesting passive diffusive absorption of insulin from the lung. In contrast, the values for kmm,L were much larger (0.5–1.6 h-1) and decreased with increasing inhaled dose. Therefore, it is likely that dose-dependent saturable lung metabolism controls the value of kmm,L, alongside mucociliary clearance. As a result, the absolute bioavailability ranged from 1.5% to 4.8%. The modelling analysis also enabled derivation of increased values for both ka,L and kmm,L as a possible cause of faster absorption for deep inspiratory manoeuvres and increased absorption in smokers, and faster and increased absorption for insulin lispro.

Conclusions

Although some of these results need to be substantiated experimentally, it appears that this modelling analysis has enabled unification of the literature information associated with the kinetics and mechanisms of insulin disposition in the lung following inhalation in humans.
Footnotes
1
1 The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRef
2.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53CrossRef
3.
Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 1997; 33_(4): 285–301CrossRef
4.
Gualandi-Signorini AM, Giorgi G. Insulin formulations: a review. Eur Rev Med Pharmacol Sci 2001; 5: 73–83PubMed
5.
Farr SJ, Taylor G. Insulin inhalation: its potential as a nonparenteral method of administration. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York (NY): Marcel Dekker Inc, 1997: 371–87
6.
7.
8.
Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7: 1327–51PubMedCrossRef
9.
Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19: 3–36CrossRef
10.
Stolwijk JAJ, Hardy JD. Regulation and control in physiology. In: Mountcastle VB, editor. Medical physiology. 13th ed. St Louis (MO): CV Mosby Co, 1974: 1343–58
11.
Berger M, Rodbard D. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care 1989; 12: 725–36PubMedCrossRef
12.
Hovorka R, Powrie JK, Smith GD, et al. Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. Am J Physiol 1993; 265 (1 Pt 1): E162–75
13.
Tolic IM, Mosekilde E, Sturis J. Modeling the insulin-glucose feedback system: the significance of pulsatile insulin secretion. J Theor Biol 2000; 207: 361–75PubMedCrossRef
14.
Bilo HJG, Heine RJ, Sikkenk AC, et al. Absorption kinetics and action profiles of intermediate acting human insulins. Diabetes Res 1987; 4: 39–43PubMed
15.
Howey DC, Bowsher RR, Brunelle RL, et al. [Lys (B28), Pro (B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402PubMedCrossRef
16.
Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx® system: physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000; 2: 185–97PubMedCrossRef
17.
Köhler D, Schlüter KJ, Kerp L, et al. Nicht radioactives verfahren zur messung der lungenpermeabilität: inhalation von insulin. Atemw Lungenkr 1987; 13: 230–2
18.
Jendle JH, Karlberg BE. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 1996; 56: 555–61PubMedCrossRef
19.
Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63–72PubMedCrossRef
20.
Brunner GA, Baient B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia 2001; 44: 305–8PubMedCrossRef
21.
Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203–44PubMed
22.
Gonda I, Rubsamen RM, Farr SJ. Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin. United States Patent, US 6250298 2001 Jun 26
23.
Himmelmann A, Jendle J, Meilen A, et al. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677–82PubMedCrossRef
24.
Henry RR, Mudaliar SRD, Howland WC, et al. Inhaled insulin using AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764–9PubMedCrossRef
25.
An B, Reinhardt RR. Effects of different durations of breath holding after inhalation of insulin using the AERx® insulin diabetes management system. Clin Ther 2003; 25: 2223–44CrossRef
26.
Heubner W. Über inhalation von insulin. Klin Wochenschr 1924; 51: 2324–43
27.
Wigley FM, Londono JH, Wood SH, et al. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971; 20: 552–6PubMed
28.
Elliott RB, Edgar BW, Pilcher CC, et al. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 1987; 23: 293–7PubMed
29.
Laube BL, Georgopoulos A, Adams GK. Proving the efficacy of insulin delivered through the lungs as an aerosol. J Biopharm Sci 1991; 3: 163–9
30.
Laube BL, Georgopoulos A, Adams GK. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients [published erratum appears in JAMA 1993; 270: 324]. JAMA 1993; 269: 2106–9PubMedCrossRef
31.
Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996; 240: 93–8PubMedCrossRef
32.
Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with non-insulin-dependent diabetes mellitus. J Aerosol Med 1998; 11: 153–73PubMedCrossRef
33.
Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin. Diabetes Care 2002; 25: 2276–81PubMedCrossRef
34.
Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with Type 2 diabetes. Diabetes Care 2003; 26: 2842–7PubMedCrossRef
35.
Henry RR, Mudaliar S, Chu N, et al. Young and elderly Type 2 diabetic patients inhaling insulin with the AERx® insulin diabetes management system: a pharmacokinetics and pharmacodynamics comparison. J Clin Pharmacol 2003; 43: 1228–34PubMedCrossRef
36.
Sakagami M. Pulmonary insulin: a critical review of its biopharmaceutics. In: Peart J, editor. Respiratory Drug Delivery VIII Proceedings, Volume I. Raleigh (NC): Davis Horwood International Publishing Ltd, 2002: 69–77
37.
Jendle J, Karlberg BE, Persliden J, et al. Delivery and retention of an insulin aerosol produced by a new jet nebulizer. J Aerosol Med 1995; 8: 243–54PubMedCrossRef
38.
Foster LC, Kuo M, Billingsley SR. Stable glassy state powder formulations. United States Patent, US 6258341 2001 Jul 10
39.
Keener J, Sneyd J. Mathematical physiology, New York (NY): Springer, 1998
40.
Kobayashi T, Sawano S, Itoh T, et al. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 1983; 32: 331–6PubMedCrossRef
41.
Brogden RN, Heel RC. Human insulin: a review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987; 34: 350–71PubMedCrossRef
42.
Taylor G, Colthorpe P, Farr SJ. Pulmonary absorption of proteins: influence of deposition site and competitive elimination processes. In: Byron PR, Dalby RN, Farr SJ, editors. Respiratory drug delivery IV. Buffalo Grove (IL): Interpharm Press Inc, 1994: 25–30
43.
Sakagami M, Byron PR, Venitz J, et al. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. J Pharm Sci 2002; 91: 594–604PubMedCrossRef
44.
Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997; 54: 597–614PubMedCrossRef
45.
Francisco GE, Brooks PJ. Diabetes mellitus. In: Di Piro JT, Tabbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, editors. Pharmacotherapy. 2nd ed. Chap. 66. New York (NY): Elsevier Science Publishing Co Inc, 1992: 1121–45
46.
Shapiro DL, Livingston JN, Maniscako WM, et al. Insulin receptors and insulin effects on type II alveolar epithelial cells. Biochim Biophys Acta 1986; 885: 216–20PubMedCrossRef
47.
Iozzo P, Osman S, Glaser M, et al. In vitro imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodinine-124 labeled human insulin. Nucl Med Biol 2002; 29: 73–82PubMedCrossRef
48.
Yamahara H, Lehr CM, Lee VHL, et al. Fate of insulin during transit across rat alveolar epithelial cell monolayers. Eur J Pharm Biopharm 1994; 40: 294–8
49.
Egan EA. Response of alveolar epithelial solute permeability to changes in lung inflation. J Appl Physiol 1980; 49: 1032–6PubMed
50.
Liu F, Kildsig DO, Mitra AK. Pulmonary biotransformation of insulin in rat and rabbit. Life Sci 1992; 51: 1683–9PubMedCrossRef
51.
Yamamoto A, Umemori S, Muranishi M. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors. J Pharm Pharmacol 1994; 46: 14–8PubMedCrossRef
52.
Hsu MC, Bai JP. Investigation into the presence of insulindegrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats. J Pharm Pharmacol 1998; 50: 507–14PubMedCrossRef
53.
Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75: 433–8PubMedCrossRef
54.
Olseni L, Wollmer P. Immediate effects of ethanol on mucociliary clearance in healthy men. Respiration 1992; 59: 151–4PubMedCrossRef
55.
Jones JG, Minty BD, Lawler P, et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; I: 66–8CrossRef
56.
Dolovich MB, Cockcroft DW, Coates G. Aerosols in diagnosis: ventilation, airway penetrance, epithelial permeability, mucociliary transport and airway responsiveness. In: Moren F, Dolovich MB, Newhouse MT, Newman SP, editors. Aerosols in medicine. 2nd ed. Amsterdam, The Netherlands: Elsevier Science Publishing BV, 1993: 195–234
57.
Vastag E, Matthys H, Zsamboki G, et al. Mucociliary clearance in smokers. Eur J Respir Dis 1986; 68: 107–13PubMed
58.
Cohen GM. Pulmonary metabolism of foreign compounds: its role in metabolic activation. Environ Health Perspect 1990; 85: 31–41PubMedCrossRef
59.
Reilly Jr JJ, Chen P, Sailor LZ, et al. Cigarette smoking induces an elastolytic cysteine proteinase in macrophages distinct from cathepsin L. Am J Physiol 1991; 261: L41–8PubMed
60.
van Der Velden VH, Naber BA, van Hal PT, et al. Peptidases in the asthmatic airways. Adv Exp Med Biol 2000; 477: 413–30PubMedCrossRef
61.
Liu F, Shao Z, Kildsig DO, et al. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993; 10: 228–32PubMedCrossRef
Metadata
Title
Insulin Disposition in the Lung Following Oral Inhalation in Humans
A Meta-Analysis of its Pharmacokinetics
Author
Dr Masahiro Sakagami
Publication date
01-07-2004
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2004
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200443080-00004